{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:49:02Z","timestamp":1782215342104,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In normal pregnancy, the soluble form of FMS-like tyrosine kinase-1 (sFLT1)\/ vascular endothelial growth factor receptor-1 (sVEGFR-1), a VEGF-trapping protein, is expressed in trophoblasts of the placenta, suggesting that it plays an important role in the physiological barrier between fetal and maternal angiogenesis, when stimulated with VEGF-A. In pathological conditions such as preeclampsia (PE), sFLT1 protein is abnormally overexpressed in trophoblasts and secreted into the serum, which could cause hypertension and proteinuria on the maternal side and growth retardation on the fetal side. Detection of an abnormal increase in serum sFLT1 during the early to middle stages of PE is essential for proper initiation of medical care. To carry out this screening for sFLT1, we developed an easier and relatively low-cost sandwich-type ELISA method using a single mixture of human serum sample with an anti-FLT1 antibody and heparin-beads, namely heparin-beads-coupled ELISA (HB-ELISA). This method takes only about 2\u00a0h, and the sFLT1 values were similar levels with commercially available recent ELISA kits: the serum sFLT1 protein was approximately 4.3-fold increased in severe PE compared with those in normal pregnancy.<\/jats:p>","DOI":"10.1038\/s41598-021-00152-6","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T21:00:21Z","timestamp":1634590821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A simple detection method for the serum sFLT1 protein in preeclampsia"],"prefix":"10.1038","volume":"11","author":[{"given":"Masabumi","family":"Shibuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sasagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"152_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physiol.00043.2008","volume":"24","author":"A Wang","year":"2009","unstructured":"Wang, A., Rana, S. & Karumanchi, S. A. Physiology (Bethesda). 24, 147\u2013158. https:\/\/doi.org\/10.1152\/physiol.00043.2008 (2009).","journal-title":"Physiology (Bethesda)."},{"key":"152_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","volume":"5","author":"BC Young","year":"2010","unstructured":"Young, B. C., Levine, R. J. & Karumanchi, S. A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173\u2013192 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"152_CR3","first-page":"519","volume":"5","author":"M Shibuya","year":"1990","unstructured":"Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519\u2013524 (1990).","journal-title":"Oncogene"},{"key":"152_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25, 581\u2013611 (2004).","journal-title":"Endocr. Rev."},{"key":"152_CR5","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705\u201310709 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"152_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0378-1119(98)00006-7","volume":"208","author":"K Kondo","year":"1998","unstructured":"Kondo, K., Hiratsuka, S., Subbalakshmi, E., Matsushime, H. & Shibuya, M. Genomic organization of the flt-1 gene encoding for Vascular Endothelial Growth Factor (VEGF) Receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 208, 297\u2013305 (1998).","journal-title":"Gene"},{"key":"152_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR1\/Flt-1): A dual regulator for angiogenesis. Angiogenesis 9, 225\u2013230 (2006).","journal-title":"Angiogenesis"},{"key":"152_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1095\/biolreprod59.6.1540","volume":"59","author":"DE Clark","year":"1998","unstructured":"Clark, D. E. et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 59, 1540\u20131548 (1998).","journal-title":"Biol. Reprod."},{"key":"152_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/mend.13.4.0265","volume":"13","author":"Y He","year":"1999","unstructured":"He, Y. et al. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol. 13, 537\u2013545 (1999).","journal-title":"Mol. Endocrinol."},{"key":"152_CR10","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1096\/fj.07-8809com","volume":"21","author":"CP Thomas","year":"2007","unstructured":"Thomas, C. P., Andrews, J. I. & Liu, K. Z. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J. 21, 3885\u20133895 (2007).","journal-title":"FASEB J."},{"key":"152_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1161\/CIRCRESAHA.108.171504","volume":"102","author":"S Sela","year":"2008","unstructured":"Sela, S. et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102, 1566\u20131574 (2008).","journal-title":"Circ. Res."},{"key":"152_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.placenta.2008.12.010","volume":"30","author":"M Heydarian","year":"2009","unstructured":"Heydarian, M. et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30, 250\u2013255 (2009).","journal-title":"Placenta"},{"key":"152_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1161\/HYPERTENSIONAHA.110.164079","volume":"58","author":"J Jebbink","year":"2011","unstructured":"Jebbink, J. et al. Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension 58, 70\u201376 (2011).","journal-title":"Hypertension"},{"key":"152_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.placenta.2008.10.006","volume":"30","author":"A Rajakumar","year":"2009","unstructured":"Rajakumar, A. et al. Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 30, 25\u201334 (2009).","journal-title":"Placenta"},{"key":"152_CR15","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1210\/jc.2009-0017","volume":"94","author":"CP Thomas","year":"2009","unstructured":"Thomas, C. P. et al. A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J. Clin. Endocrinol. Metab. 94, 2524\u20132530 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"152_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649\u2013658 (2003).","journal-title":"J. Clin. Invest."},{"key":"152_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1210\/jc.2002-021942","volume":"88","author":"K Koga","year":"2003","unstructured":"Koga, K. et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348\u20132351 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"152_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672\u2013683 (2004).","journal-title":"N. Engl. J. Med."},{"key":"152_CR19","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"152_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cell.2012.08.037","volume":"151","author":"J Jin","year":"2012","unstructured":"Jin, J. et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 151, 384\u2013399 (2012).","journal-title":"Cell"},{"key":"152_CR21","doi-asserted-by":"publisher","first-page":"e00324","DOI":"10.7554\/eLife.00324","volume":"2","author":"L Luo","year":"2013","unstructured":"Luo, L. et al. Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife 2, e00324. https:\/\/doi.org\/10.7554\/eLife.00324 (2013).","journal-title":"Elife"},{"key":"152_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2183\/pjab.87.167","volume":"87","author":"M Shibuya","year":"2011","unstructured":"Shibuya, M. Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 87, 167\u2013178 (2011).","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"152_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S1701-2163(15)30511-9","volume":"36","author":"A Doherty","year":"2014","unstructured":"Doherty, A. et al. Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1\/PlGF ratio before the onset of early severe preeclampsia. J. Obstet. Gynaecol. Can. 36, 692\u2013700. https:\/\/doi.org\/10.1016\/S1701-2163(15)30511-9 (2014).","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"152_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/10641955.2014.982331","volume":"34","author":"M Hund","year":"2015","unstructured":"Hund, M. et al. Influence of the sFlt-1\/PlGF ratio on clinical decision-making in women with suspected preeclampsia\u2014The PreOS study protocol. Hypertens. Pregnancy. 34, 102\u2013115. https:\/\/doi.org\/10.3109\/10641955.2014.982331 (2015).","journal-title":"Hypertens. Pregnancy."},{"key":"152_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/10641955.2016.1237642","volume":"36","author":"P Tang","year":"2017","unstructured":"Tang, P. et al. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia. Hypertens. Pregnancy 36, 48\u201352. https:\/\/doi.org\/10.1080\/10641955.2016.1237642 (2017).","journal-title":"Hypertens. Pregnancy"},{"key":"152_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1349-7006.1997.tb00463.x","volume":"88","author":"K Tanaka","year":"1997","unstructured":"Tanaka, K., Yamaguchi, S., Sawano, A. & Shibuya, M. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn. J. Cancer Res. 88, 867\u2013876 (1997).","journal-title":"Jpn. J. Cancer Res."},{"key":"152_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1056\/NEJMoa055352","volume":"355","author":"RJ Levine","year":"2006","unstructured":"Levine, R. J. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992\u20131005 (2006).","journal-title":"N. Engl. J. Med."},{"key":"152_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jri.2009.09.001","volume":"82","author":"JM Foidart","year":"2009","unstructured":"Foidart, J. M., Schaaps, J. P., Chantraine, F., Munaut, C. & Lorquet, S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia\u2013a step forward but not the definitive answer. J. Reprod. Immunol. 82, 106\u2013111. https:\/\/doi.org\/10.1016\/j.jri.2009.09.001 (2009).","journal-title":"J. Reprod. Immunol."},{"key":"152_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/humrep\/den114","volume":"23","author":"C Munaut","year":"2008","unstructured":"Munaut, C. et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum. Reprod. 23, 1407\u20131415. https:\/\/doi.org\/10.1093\/humrep\/den114 (2008).","journal-title":"Hum. Reprod."},{"key":"152_CR30","doi-asserted-by":"publisher","first-page":"17375","DOI":"10.1038\/s41598-018-35745-1","volume":"8","author":"T Sasagawa","year":"2018","unstructured":"Sasagawa, T. et al. HIF-2\u03b1, but not HIF-1\u03b1, mediates hypoxia-induced up-regulation of Flt-1 gene expression in placental trophoblasts. Sci. Rep. 8, 17375. https:\/\/doi.org\/10.1038\/s41598-018-35745-1 (2018).","journal-title":"Sci. Rep."},{"key":"152_CR31","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1210\/en.2004-0533","volume":"145","author":"T Nagamatsu","year":"2004","unstructured":"Nagamatsu, T. et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145, 4838\u20134845 (2004).","journal-title":"Endocrinology"},{"key":"152_CR32","first-page":"e1","volume":"396","author":"F Lu","year":"2007","unstructured":"Lu, F. et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 396, e1-7 (2007).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"152_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","volume":"124","author":"R Thadhani","year":"2011","unstructured":"Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940\u2013950 (2011).","journal-title":"Circulation"},{"key":"152_CR34","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/jog.12760","volume":"41","author":"B Nakakita","year":"2015","unstructured":"Nakakita, B. et al. Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks\u2019 gestation. J. Obstet. Gynaecol. Res. 41, 1661\u20131663. https:\/\/doi.org\/10.1111\/jog.12760 (2015).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"152_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1681\/ASN.2015020157","volume":"27","author":"R Thadhani","year":"2016","unstructured":"Thadhani, R. et al. Removal of soluble Fms-Like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903\u2013913. https:\/\/doi.org\/10.1681\/ASN.2015020157 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"152_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvs136","volume":"153","author":"M Shibuya","year":"2013","unstructured":"Shibuya, M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 153, 13\u201319 (2013).","journal-title":"J. Biochem."},{"key":"152_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12944-018-0698-4","volume":"17","author":"C Contini","year":"2018","unstructured":"Contini, C. et al. Lipoprotein turnover and possible remnant accumulation in preeclampsia: Insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study. Lipids Health Dis. 17, 49. https:\/\/doi.org\/10.1186\/s12944-018-0698-4 (2018).","journal-title":"Lipids Health Dis."},{"key":"152_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.preghy.2018.04.007","volume":"12","author":"K Winkler","year":"2018","unstructured":"Winkler, K. et al. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study. Pregnancy Hypertens. 12, 136\u2013143. https:\/\/doi.org\/10.1016\/j.preghy.2018.04.007 (2018).","journal-title":"Pregnancy Hypertens."},{"key":"152_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.placenta.2014.12.006","volume":"36","author":"DR Armant","year":"2015","unstructured":"Armant, D. R. et al. Reduced expression of the epidermal growth factor signaling system in preeclampsia. Placenta 36, 270\u2013278. https:\/\/doi.org\/10.1016\/j.placenta.2014.12.006 (2015).","journal-title":"Placenta"},{"key":"152_CR40","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1080\/14767058.2018.1441279","volume":"32","author":"I Ulu","year":"2019","unstructured":"Ulu, I. et al. Maternal serum thrombospondin-1 is significantly altered in cases with established preeclampsia. Matern. Fetal Neonatal Med. 32, 2543\u20132546. https:\/\/doi.org\/10.1080\/14767058.2018.1441279 (2019).","journal-title":"Matern. Fetal Neonatal Med."},{"key":"152_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5455\/2320-1770.ijrcog20130927","volume":"2","author":"PD Sarkar","year":"2013","unstructured":"Sarkar, P. D. & Sogani, S. Association of antithrombin-III and platelet count with pregnancy induced hypertension. Int. J. Reprod. Contracept. Obstet. Gynecol. 2, 398\u2013401 (2013).","journal-title":"Int. J. Reprod. Contracept. Obstet. Gynecol."},{"key":"152_CR42","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/sj.onc.1203533","volume":"19","author":"S Kanno","year":"2000","unstructured":"Kanno, S. et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19, 2138\u20132146 (2000).","journal-title":"Oncogene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00152-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:46:07Z","timestamp":1670085967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00152-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00152-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. received a research fund from Denka Seiken. Co. Ltd., Tokyo, Japan.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20613"}}